Gossamer bio announces second quarter 2022 financial results and provides business update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter ended june 30, 2022 and provided a business update. “everyone at gossamer is looking forward to the upcoming torrey phase 2 results, as we actively prepare for seralutinib's next steps in cl
GOSS Ratings Summary
GOSS Quant Ranking